Evidence map›Paper›PMID 41929097›Full record

ArticlebioRxiv : the preprint server for biology2026

Developmental determinants of male bias in medulloblastoma.

Luca Bianchini, Ruijie Xu, David Filipovic, Patricia Benites Goncalves da Silva, Laura Sieber, Vuslat Akçay, Frederik Arnskötter, Piyush Joshi, Jana Nolle, Taha Soliman and 9 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Luca BianchiniHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.ORCID 0009-0005-9059-5312
Ruijie XuCenter of Excellence in Neuro-Oncology Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-3364-1587
David FilipovicCenter of Excellence in Neuro-Oncology Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-4421-1654
Patricia Benites Goncalves da SilvaHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.ORCID 0000-0001-9153-9869
Laura SieberHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Vuslat AkçayHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.ORCID 0000-0002-6704-4353
Frederik ArnskötterHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.ORCID 0009-0006-9420-0485
Piyush JoshiHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Jana NolleHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Taha SolimanCenter of Excellence in Neuro-Oncology Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-3185-3092
Ran TaoCenter of Excellence in Neuro-Oncology Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.
Alexandra ScheuingHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.ORCID 0009-0006-9046-3114
Konstantin OkonechnikovHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Alexander AtamianDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Marc ZuckermannHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Giles W RobinsonDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
Giorgia QuadratoDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Paul A NorthcottCenter of Excellence in Neuro-Oncology Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.
Lena M KutscherHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.ORCID 0000-0002-1130-4582

Funding

Mapping the Cerebellar Origins of Medulloblastoma SubgroupsR01CA270785 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Paul Northcott · 2023 to 2026
$2.8M
NCI NIH HHS R01 CA270785
6 · The paper itself

Abstract

Boys experience an overall increased incidence of several childhood cancers, including medulloblastoma, a clinically heterogeneous cerebellar tumor. In subtypes of Group 3 and Group 4 medulloblastoma, males are three times more prevalent than females. As medulloblastoma is suspected to initiate during fetal development, we hypothesized that this sex bias reflects a combination of prenatal, sex-specific developmental processes and somatic alterations. To test these hypotheses, we compiled a large multi-omics dataset from children with medulloblastoma, which revealed sex-specific alterations, including frequent loss of the inactive X chromosome in females with Group 4. Generation of a sex-matched single-cell transcriptome atlas of the developing murine cerebellum enabled investigation of putative developmental factors underlying sex bias. Progenitors giving rise to Group 3/4 subgroups were more abundant, more proliferative, and harbored more open chromatin for recruitment of LMX1A and OTX2, master transcription factors defining Group 3/4 idefntity. Advanced genetically engineered mouse models and human cerebellar organoids were leveraged to determine whether sexual dimorphism arises from intrinsic or extrinsic factors. These models showed that the XY genotype contributed to the phenotype, but the predominant effect was driven by presence of the male gonadal hormone testosterone. Our findings provide a sex-specific genetic and neurodevelopmental explanation for male bias in an aggressive pediatric brain tumor. Outcomes from this study may inform novel treatment strategies delivered according to sex and are likely to be broadly applicable to other sex-biased malignancies arising in early life.

Identifiers

PMID41929097
PMCPMC13041814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.